2. Signaling Pathways
  3. GPCR/G Protein
  4. Platelet-activating Factor Receptor (PAFR)

Platelet-activating Factor Receptor (PAFR)

The platelet-activating factor receptor (PAFR) is a G-protein-coupled receptor involved in both normal physiological and numerous pathophysiological processes. PAFR responds to platelet-activating factor (PAF), a phospholipid mediator of cell-to-cell communication that exhibits diverse physiological effects. Stimulation of the PAFR via binding of platelet-activating factor (PAF) elicits diverse and potent biological activities and plays a profound role in acute inflammation, allergic disorders, endotoxic shock, and anaphylaxis. PAF is a potent and versatile mediator of inflammation that is produced by numerous cell types and tissues, and particularly by leukocytes.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-118019
    Scandenolide
    Scandenolide is a sesquiterpene lactone that can be found in Philippines medicinal plant Mikania cordata. Scandenolide inhibits leukotriene and platelet activating factor synthesis in leukocytes.
    Scandenolide
  • HY-134101
    2-O-Ethyl PAF C-16
    2-O-Ethyl PAF C-16 is a homolog of PAF and a competitive ligand for PAF receptor (Platelet-activating Factor Receptor (PAFR)). 2-O-Ethyl PAF C-16 inhibits the binding of the PAF antagonist WEB 2086 (HY-108634) to the PAF receptor with an IC50 of 21 nM.
    2-O-Ethyl PAF C-16
  • HY-126551
    Butenoyl-PAF
    		Agonist
    Butenoyl-PAF is a phospholipid analog of platelet activating factor (PAF-like) that is generated in oxidized low-density lipoprotein (DLDR). Butenoyl-PAF can activate cells that express human PAF receptors, such as neutrophils, monocytes, and platelets, and it stimulates an increase in intracellular calcium ion concentration.
    Butenoyl-PAF
  • HY-167719
    Dersalazine
    		Inhibitor
    Dersalazine (UR-12746 free base) is an inhibitor of platelet-activating factor, exhibiting intestinal anti-inflammatory activity and potential efficacy in treating ulcerative colitis.
    Dersalazine
  • HY-123399
    Ro 19-1400
    		Antagonist
    Ro 19-1400 is a platelet-activating factor antagonist that directly inhibits immunoglobulin E-dependent mediator release.
    Ro 19-1400
  • HY-N1620
    1-Cinnamoylpyrrolidine
    		Inhibitor
    1-Cinnamoylpyrrolidine (Compound 3), a crude extract prepared from Piper caninum, is a DNA strand scission agent, induces the relaxation of supercoiled pBR322 plasmid DNA. 1-Cinnamoylpyrrolidine (Compound 4) inhibits platelet aggregation induced by PAF with an IC50 of 37.3 μM.
    1-Cinnamoylpyrrolidine
  • HY-124887
    L 651142
    		Antagonist
    L 651142 is a weak platelet activating factor (PAF) receptor antagonist. L 651142 inhibits the binding of [3H]PAF to rabbit platelet, human platelet or human lung membranes with Kis of 0.839 μM, 1.82 μM, 3.64 μM, respectively.
    L 651142
  • HY-106038
    Acopafant
    		Antagonist
    Acopafant (Dacopafant; RP 55778) is a potent platelet-activating factor antagonist. Acopafant inhibits the induction of human immunodeficiency virus (HIV) expression in chronically infected cells. Acopafant has the potential for the research of HIV infection.
    Acopafant
  • HY-125309
    ABT-299
    		Antagonist
    ABT-299 is a prodrug of a platelet-activating factor (PAF) antagonist that exhibits significant inhibitory activity on PAF-induced β-platelet globulin release in vitro after in vivo administration in humans, an effect that may be partially attributed to the pyridine-N-oxide metabolite.
    ABT-299
  • HY-106062
    CV 3988
    		Inhibitor
    CV 3988 is a specific inhibitor of platelet-activating factor (PAF).
    CV 3988
  • HY-N11932
    Piperulin A
    		Inhibitor
    Piperulin A is a potent inhibitor of PAFR. Piperulin A inhibits the specific binding of PAFR on isolated rabbit platelet plasma membranes with an IC50 of 7.3 μM.
    Piperulin A
  • HY-N3054
    Pinusolidic acid
    		Inhibitor
    Pinusolidic acid is a platelet-activating factor (PAF) inhibitor with an IC50 of 23 μM.
    Pinusolidic acid
  • HY-N14932
    Aggreceride A
    		Inhibitor
    Aggreceride A is a platelet aggregation inhibitor. Aggreceride A shows an inhibitory activity against aggregation induced by Adenosine 5'-diphosphate (ADP) (HY-W010918), Arachidonic acid (HY-109590) and PAF (platelet activating factor), but was less active against aggregation induced by collagen.
    Aggreceride A
  • HY-123505
    Dersalazine sodium
    		Antagonist
    Dersalazine (sodium) is a platelet-activating factor (PAF) antagonist. Dersalazine (sodium) can exert intestinal anti-inflammatory activity in rodent colitis models by downregulating IL-17 expression.
    Dersalazine sodium
  • HY-122126
    BN 52111
    		Antagonist
    BN 52111 is a potent platelet-activating factor (PAF) receptor antagonist.
    BN 52111
  • HY-133003
    L662,025
    		Antagonist
    L662,025 is a specific, photolabile and irreversible Platelet-activating factor (PAF-receptor) antagonist, with IC50 values of 5.6 μM (platelet aggregation) and 1 μM (receptor binding), respectively.
    L662,025
  • HY-N14933
    Aggreceride B
    		Inhibitor
    Aggreceride B is a platelet aggregation inhibitor. Aggreceride B shows an inhibitory activity against aggregation induced by Adenosine 5'-diphosphate (ADP) (HY-W010918), Arachidonic acid (HY-109590) and PAF (platelet activating factor), but was less active against aggregation induced by collagen.
    Aggreceride B
  • HY-117636
    (Rac)-L-659989
    		Antagonist
    (Rac)-L-659989 is the racemate of L-659989 (HY-121394). L-659989 s an orally active, extremely potent, selective and competitive platelet activating factor (PAF) receptor antagonist.
    (Rac)-L-659989
  • HY-119035
    R-75317
    		Antagonist
    R-75317 is a specific platelet-activating factor (PAF) antagonist. R-75317 can prevent the decline in creatinine clearance (Ccr) in a rat model of glomerulonephritis induced by the injection of antibodies extracted from rabbits against rat glomerular basement membrane (GBM) antigens, delay the onset of proteinuria, and improve glomerular hypertrophy, mesangial matrix proliferation, and interstitial fibrosis. R-75317 may be useful in the study of glomerulonephritis.
    R-75317
  • HY-N15271
    Oxopurpureine
    Oxopurpureine is an oxoaporphine with antiplatelet aggregation activity. Oxopurpureine inhibits collagen, thrombin and arachidonic acid-induced platelet aggregation and can be utilized in relevant research.
    Oxopurpureine
Cat. No. Product Name / Synonyms Application Reactivity